62 
Day 2 tests: private provider requirements 
7. —(1) For the purposes of paragraph 6(1)(b)(iii), a private provider complies with this 
paragraph where— 
(a)  they comply with the requirements of paragraph 3(1)(a) and (e) to (h) of Schedule 10 as if 
any reference in those provisions to an appropriate test were a reference to a day 2 test; 
(b)  if the provider is a laboratory that conducts diagn ostic test evaluation for testing in 
accordance with this Schedule, they have made a declaration to the Department of Health 
and Social Care that they meet the minimum standards for private sector-provided testing 
at https://support-covid-19-testing.dhsc.gov.uk/InternationalTesting; 
(c)  they have provided the Department of Health and Soc ial Care with a list of all 
organisations that they work with (whether by sub-c ontract or otherwise) to carry out the 
testing service or to carry out genomic sequencing,  indicating the nature of the service 
that each organisation is providing, and kept that list updated as appropriate; 
(d)  the person responsible for the taking of samples me ets the relevant requirements for 
accreditation to ISO standard 15189 or ISO/IEC stan dard 17025 in respect of the taking 
of samples; 
(e)  the laboratory used by the test provider for the pr ocessing of samples meets the relevant 
requirements for ISO standard 15189 or ISO/IEC stan dard 17025 in respect of the 
evaluation of the established molecular detection m ethod and the genomic sequencing of 
samples; 
(f)  they receive the information required by paragraph 10(3) or (4) (as appropriate), and if 
they administer the test to P, they do so no later than the end of the second day after the 
day on which P arrived in England; 
(g)  each day, they notify the Secretary of State in writing of— 
(i)  the number of tests they sold on that day, and 
(ii)  in relation to each test sold on that day— 
(aa)  the date of the arrival in England of the person in  respect of whom the test 
was sold, and 
(bb)  whether the person in respect of whom the test was sold is a category 1 arrival 
or not; 
(h)  they sequence each sample with a cycle threshold less than 30 (equivalent to ~1,000 viral 
genome copies per millilitre); 
(i)  in respect of the sequencing of samples, they must secure a reference genome coverage 
breadth of at least 50% and at least 30 times coverage; 
(j)  on a request by the Secretary of State or the COVID -19 Genomics UK Consortium, they 
make samples available for the purpose of dual sequencing; 
(k)  they preserve and transport samples in a manner that enables genome sequencing; 
(l)  they have in place a process to remove human reads from any data submitted in a 
notification to Public Health England pursuant to t he Health Protection (Notification) 
Regulations 2010; and 
(m)  if they arrange with another person (“X”) for X to carry out any element of the single 
end-to-end testing service on their behalf, the tes t provider ensures that X complies with 
the following so far as relevant to the carrying out of that element— 
(i)  paragraph 3(1)(e) to (h) of Schedule 10 as applied by paragraph (a) of this sub-
paragraph, 
(ii)  paragraph (c) to (l) of this sub-paragraph, 
(iii)  paragraph 11(2), (3) and (4). 
(2)  For the purposes of sub-paragraph (1)(m), “single e nd-to-end testing service” has the 
meaning given in paragraph 3(2)(c) of Schedule 10.